Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPA3 | P15088 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883092 | 1.00 | CPA1 (0.53) | CPA1CPB1CPA3CPB2SIGMAR1 | |
| SCHEMBL4883084 | 1.00 | CPA1 (0.53) | CPA1CPB1CPA3CPB2SIGMAR1 | |
| SCHEMBL4887404 | 0.92 | OPRD1 (0.47) | CPA1CPB1CPA3CPB2SIGMAR1 | |
| SCHEMBL4886772 | 0.92 | OPRD1 (0.47) | CPA1CPB1CPA3CPB2SIGMAR1 | |
| SCHEMBL4886780 | 0.92 | OPRD1 (0.47) | CPA1CPB1CPA3CPB2SIGMAR1 | |
| SCHEMBL4888634 | 0.91 | CPA1 (0.45) | CPA1CPB1CPA3CPB2SIGMAR1 | |
| SCHEMBL4884678 | 0.91 | MME (0.54) | CPA1CPB1CPA3CPB2MME | |
| SCHEMBL4877339 | 0.91 | DPP7 (0.56) | CPA1CPB1CPA3CPB2MME | |
| SCHEMBL4878562 | 0.91 | DPP7 (0.56) | CPA1CPB1CPA3CPB2MME | |
| SCHEMBL4887308 | 0.91 | MME (0.54) | CPA1CPB1CPA3CPB2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493819-B1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | UBE INDUSTRIES (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-7449325-B2 | Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof | UBE INDUSTRIES, LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1493819-A1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | Ube Industries, Ltd. (JP) | 2005-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | CYP8B1, SRR, HM13 | CPA1 508/4885CPB1 507/4885CPA3 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.